Carpal Tunnel Syndrome and Amyloidosis
Launched by CORPORACION PARC TAULI · Jan 27, 2020
Trial Information
Current as of May 19, 2025
Unknown status
Keywords
ClinConnect Summary
Carpal tunnel syndrome (CTS) can be caused by the deposition and accumulation of misfolded proteins called amyloid and is often an early manifestation of systemic amyloidosis.
Patients with cardiac amyloidosis often have carpal tunnel syndrome that precedes cardiac manifestations by several years, and many patients will have undergone surgery for idiopathic carpal tunnel syndrome since the protein also deposits in the transversal carpal ligament of the hand.
The investigators sought to identify the prevalence and type of amyloid deposits in patients undergoing carpal tunnel surgery and ev...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients undergoing carpal tunnel syndrome surgery
- Exclusion Criteria:
- • None
About Corporacion Parc Tauli
Corporación Parc Taulí is a leading healthcare organization based in Sabadell, Spain, known for its commitment to advancing medical research and clinical excellence. With a focus on innovative healthcare solutions, the organization integrates cutting-edge technology and multidisciplinary collaboration to enhance patient outcomes. As a sponsor of clinical trials, Corporación Parc Taulí emphasizes ethical practices, rigorous scientific methodologies, and robust data management to contribute to the development of new therapies and improve healthcare standards. Their dedication to research and patient care positions them as a vital player in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sabadell, Barcelona, Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials